Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DN1508052-01 plus toripalimab in advanced solid tumors
CTR20213413Phase 2Active
- Sponsor
- Dino Pharmaceutical Technology
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DN1508052, toripalimab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Dino Pharmaceutical Technology. Started Oct 2022; status: active.
02
Drugs
DN1508052toripalimab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20213413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213413.